David Keller
Family Medicine · Richmond, INNPI 1154409282
Payments from drug & device makers
Across 139 payments — averaging $14.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$345
- Novo Nordisk$247
- Lilly USA, LLC$224
- Boehringer Ingelheim$164
- Gilead$121
- GSK$119
- plus $750 from 20 others
What the payments were for
- Food & beverage$1,970100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $345 |
| Novo Nordisk | 18 | $247 |
| Lilly USA, LLC | 16 | $224 |
| Boehringer Ingelheim | 12 | $164 |
| Gilead | 7 | $121 |
| GSK | 9 | $119 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $86 |
| Otsuka America Pharmaceutical, Inc. | 5 | $85 |
| Bayer | 4 | $59 |
| AstraZeneca | 4 | $54 |
| Mannkind Corporation | 2 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Novartis | 2 | $31 |
| Sanofi Pasteur Inc. | 2 | $30 |
| Pfizer | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Corium, LLC | 2 | $26 |
| Amgen | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $21 |
| Alkermes, Inc. | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
How this compares
$1,970 in reported general payments places this provider in the 70th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $27,361 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,146 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $8,607 |
| Atorvastatin Calcium | 120 | $807 |
| Buspirone Hcl | 13 | $282 |
| Omeprazole | 35 | $253 |
| Amlodipine Besylate | 56 | $222 |
| Lisinopril | 47 | $211 |
| Tamsulosin Hcl | 23 | $185 |
| Levothyroxine Sodium | 32 | $156 |
| Pantoprazole Sodium | 15 | $149 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 40 | $91 |
| Ropinirole Hcl | 13 | $80 |
| Losartan Potassium | 20 | $77 |
| Metoprolol Tartrate | 17 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $247 | $27,36117 claims |
| GSKTrelegy Ellipta | $119 | $11,14618 claims |
| AstraZenecaBreztri Aerosphere | $54 | $8,60712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Richmond
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.